Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt’s lymphoma in vitro and in vivo

Kardosh, Adel; Wang, Weijun; Uddin, Jasim; Petasis, Nicos A.; Hofman, Florence M.; Chen, Thomas C.; Schönthal, Axel H.

doi:10.4161/cbt.4.5.1699

Cited by 76 publications

(105 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, in our own studies, we did not detect substantial celecoxib-mediated inhibition of PDK1 (Kardosh et al, 2005). Furthermore, celecoxib induced apoptosis with equal efficacy in mouse embryonic fibroblasts lacking both PDK1 alleles as compared to their wildtype counterparts that expressed PDK1 normally (Kardosh et al, 2005).…”

Section: Pdk1 As a Target For Celecoxibmentioning

confidence: 79%

“…Furthermore, celecoxib induced apoptosis with equal efficacy in mouse embryonic fibroblasts lacking both PDK1 alleles as compared to their wildtype counterparts that expressed PDK1 normally (Kardosh et al, 2005). Moreover, the downregulation of phosphorylation of the primary PDK1 target Akt, which has been reported in several celecoxib-treated tumour cell lines (Hsu et al, 2000;Arico et al, 2002;Song et al, 2002;Kulp et al, 2004), is not consistently observed in all tumour cells (Kern et al, 2002;Kardosh et al, 2005), even though apoptosis is similarly induced by drug treatment.…”

Section: Pdk1 As a Target For Celecoxibmentioning

confidence: 92%

See 1 more Smart Citation

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

Schönthal

2007

Br J Cancer

View full text Add to dashboard Cite

Celecoxib (Celebrex s ) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain. However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-2-inhibitory activity. This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in mediating this drug's antitumour effects.

show abstract

Section: Pdk1 As a Target For Celecoxibmentioning

confidence: 79%

Section: Pdk1 As a Target For Celecoxibmentioning

confidence: 92%

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

Schönthal

2007

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…next, we evaluated whether celecoxib inhibited cell proliferation in a coX-2-dependent or -independent manner by examining the effect of DMc on the proliferation of canine mammary tumor cells. DMc is a structural isomer of celecoxib that lacks coX-2-inhibitory activity (25). as shown in fig.…”

Section: Resultsmentioning

confidence: 99%

Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms

Tamura

Saito

Murata

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. celecoxib plays antitumor roles via multiple mechanisms in a variety of human cancers. the aim of this study was to clarify the mechanism of action of celecoxib in canine mammary tumors. We examined the antitumor effects of celecoxib in aZacB canine mammary tumor cells expressing low levels of cyclooxygenase-2 (coX-2) to minimize the effect of coX-2 on its activity. our data revealed that celecoxib inhibited cell proliferation mainly via COX-2-independent mechanisms. Specifically, celecoxib decreased the proportion of cells in S phase and increased g2/M arrest, which was associated with increased expression of the cyclin-dependent kinase inhibitors (cDKis) p21 and p27. in addition, treatment with celecoxib downregulated coX-2 expression, and induced apoptosis via both the intrinsic and extrinsic pathways. These findings suggest that celecoxib might be a useful agent for the treatment of canine mammary tumors, regardless of coX-2 expression. in the future, it might be possible to use a combination of celecoxib and other antitumor agents to treat canine mammary tumors.

show abstract

“…Thus alternative inhibitors that mimic the anti‐tumor effect of COX‐2, but do not share these cardiovascular risks are desirable. 2,5‐dimethyl celecoxib (DMC), is a non‐cyclooxygenase‐2 inhibitor analog of celecoxib that can mimic the anti‐tumor effect of celexib 163. Ferrario et al discovered that DMC enhanced PDT tumoricidal responsiveness without altering COX‐2 activity 152.…”

Section: Combining Phototherapy With Novel Anti‐cancer Agentsmentioning

confidence: 99%

Chemophototherapy: An Emerging Treatment Option for Solid Tumors

et al. 2016

View full text Add to dashboard Cite

Near infrared (NIR) light penetrates human tissues with limited depth, thereby providing a method to safely deliver non‐ionizing radiation to well‐defined target tissue volumes. Light‐based therapies including photodynamic therapy (PDT) and laser‐induced thermal therapy have been validated clinically for curative and palliative treatment of solid tumors. However, these monotherapies can suffer from incomplete tumor killing and have not displaced existing ablative modalities. The combination of phototherapy and chemotherapy (chemophototherapy, CPT), when carefully planned, has been shown to be an effective tumor treatment option preclinically and clinically. Chemotherapy can enhance the efficacy of PDT by targeting surviving cancer cells or by inhibiting regrowth of damaged tumor blood vessels. Alternatively, PDT‐mediated vascular permeabilization has been shown to enhance the deposition of nanoparticulate drugs into tumors for enhanced accumulation and efficacy. Integrated nanoparticles have been reported that combine photosensitizers and drugs into a single agent. More recently, light‐activated nanoparticles have been developed that release their payload in response to light irradiation to achieve improved drug bioavailability with superior efficacy. CPT can potently eradicate tumors with precise spatial control, and further clinical testing is warranted.

show abstract

Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt’s lymphoma in vitro and in vivo

Cited by 76 publications

References 59 publications

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms

Chemophototherapy: An Emerging Treatment Option for Solid Tumors

Contact Info

Product

Resources

About